Summary & Overview
CPT 80432: Glucose and C‑peptide Testing During Insulin Stimulation
CPT code 80432 represents a focused diagnostic laboratory protocol that measures glucose and C‑peptide in five timed blood samples around insulin administration, with a single baseline insulin measurement. Nationally, this code is used to evaluate insulin secretion and glucose dynamics in endocrine and metabolic assessments, informing diagnoses such as hypoglycemia disorders, insulinoma evaluation, and complex diabetes assessments. Its use matters for accurate clinical interpretation, appropriate laboratory sequencing, and payer coverage determinations across major national plans.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the test, expected sites of service, and the typical laboratory workflow tied to the code. The publication also summarizes common billing considerations, coding relationships, and what to expect from payer coverage policies and adjudication patterns at a national level.
This piece provides benchmarks for utilization and reimbursement themes, flags common documentation elements that support medical necessity, and outlines how the assay fits into broader endocrine diagnostic pathways. Data not available in the input for some specific payer policy details and related codes is noted where applicable.
Billing Code Overview
CPT code 80432 describes a laboratory testing protocol in which a lab analyst measures glucose and C-peptide levels in each of five blood samples: one sample drawn before and four samples drawn after the administration of insulin. The protocol also includes a single insulin measurement taken once for a baseline level.
-
Service type: Diagnostic laboratory endocrine testing involving serial blood sampling during an insulin-stimulated protocol.
-
Typical site of service: Hospital outpatient laboratory or independent outpatient clinical laboratory where timed blood draws and specialized endocrine assays are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to an endocrinology clinic for evaluation of suspected endogenous hyperinsulinemic hypoglycemia (for example, insulinoma) or for assessment of unexplained recurrent symptomatic hypoglycemia. The clinical workflow begins with an endocrinologist or hospitalist ordering a supervised insulin tolerance or provocative test that requires serial blood draws: one baseline sample for insulin (and often C‑peptide and glucose) followed by administration of intravenous insulin and four timed post‑insulin blood samples to measure glucose and C‑peptide levels. A phlebotomist or trained laboratory technician collects the five samples at specified intervals; samples are sent to the clinical laboratory where an analytical technologist performs quantitative assays for glucose and C‑peptide and a single baseline insulin assay. The laboratory documents specimen receipt, assay methodology, and results in the medical record. Typical sites of service include an outpatient hospital clinic, an endocrinology clinic, or an inpatient ward where the patient can be monitored for hypoglycemia during testing. Monitoring personnel observe the patient for neuroglycopenic symptoms and treat hypoglycemia per protocol if needed. Results are interpreted by the ordering clinician to distinguish between endogenous insulin production and exogenous insulin administration, guiding further diagnostic imaging or medical management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation portion separate from the laboratory technical component. |